2005
DOI: 10.1007/s00415-005-0805-0
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of dysimmune neuropathies

Abstract: Several therapies are currently used in dys-immune neuropathies including steroids,plasma exchange (PE), high-dose intravenous immunoglobulins(IVIg), and immuno-suppressive agents (IS). Even if there is substantial evidence that these treatments may improve the course of the neuropathy, their effectiveness is far from being complete and is sometime hampered by the occurrence of associated side effects. In Guillain-Barré syndrome (GBS),IVIg and PE are similarly effective in accelerating the recovery but there i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
9
0

Year Published

2006
2006
2017
2017

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 34 publications
(9 citation statements)
references
References 117 publications
0
9
0
Order By: Relevance
“…Two large controlled trials in GBS [45,65] led to the licensing of IVIg for GBS as the first neurological disease. Although not licensed for another immune-mediated neuropathy, multifocal motor neuropathy with conduction blocks (MMN), IVIg is the treatment of choice for this disease [41]. Currently, immune mediated neuropathies are probably the most common indication for IVIg in neurological diseases.…”
Section: Use Of Ivig In Neurological Disordersmentioning
confidence: 99%
“…Two large controlled trials in GBS [45,65] led to the licensing of IVIg for GBS as the first neurological disease. Although not licensed for another immune-mediated neuropathy, multifocal motor neuropathy with conduction blocks (MMN), IVIg is the treatment of choice for this disease [41]. Currently, immune mediated neuropathies are probably the most common indication for IVIg in neurological diseases.…”
Section: Use Of Ivig In Neurological Disordersmentioning
confidence: 99%
“…These neuropathies are generally poorly responsive to treatment. Clinical improvement with plasma exchange alone or combined with cyclophosphamide has been reported [3,6]. Intravenous immunoglobulin produces only a short-lived and small benefit in some patients [7].…”
Section: Introductionmentioning
confidence: 99%
“…Rituximab is a chimeric monoclonal antibody that targets CD20. It has been successfully used in chronic neuropathies, 7 but its use in GBS has not previously been described. AMAN, one of the subtypes of GBS, has been linked to several antiganglioside antibodies that damage axons at the node of Ranvier or at the nerve terminals.…”
mentioning
confidence: 99%